OIPE IAP72
OCT 18 2005
PATENT & TRADEMARK OFFICE

PATENT

IFW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Case No. 04-736 (400/134))

In the Application of:

McSwiggen et al.

Serial No.: 10/683,990

Filing Date: October 10, 2003

For: RNA Interference Mediated Inhibition of Placental Growth Factor Gene Expression Using Short Interfering Nucleic Acid (siNA)

Examiner: TBD

Group Art Unit: 1635

Confirmation No.: 3438

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Sir:

TRANSMITTAL LETTER

In regard to the above identified application:

1. We are transmitting herewith the attached papers for the above identified new patent application:

- ☒ Supplemental Information Disclosure Statement;
- ☒ Supplemental Information Disclosure Statement (IDS) PTO-1449 Form;
- ☒ Copies of IDS Citations for S/N 10/683,990 (Total 19 foreign patents and 23 other documents); and
- ☒ Return Receipt Postcard.

2. With respect to additional fees, no additional fee is required.

3. GENERAL AUTHORIZATION: Please charge any additional fees or credit overpayment to Deposit Account No. 13-2490. A duplicate copy of this sheet is enclosed.

4. CERTIFICATE OF MAILING UNDER 37 CFR § 1.8: The undersigned hereby certifies that this Transmittal Letter and the paper, as described in paragraph 1 hereinabove, are being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450 on October 11, 2005.

By: _____
Anita J. Terpstra
Reg. No. 47,132

McDONNELL BOEHNEN HULBERT & BERGHOFF LLP
300 SOUTH WACKER DRIVE
CHICAGO, ILLINOIS 60606
TELEPHONE (312) 913-0001
FACSIMILE: (312) 913-0002

OIPE IAP72 OCT 19 2005 PATENT & TRADEMARK OFFICE

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Case No. 04-736 (400/134))

In the Application of:	
McSwiggen et al.	**Examiner: TBD**
Serial No.: 10/683,990	**Group Art Unit: 1635**
Filing Date: October 10, 2003	**Confirmation No.: 3438**
For: RNA Interference Mediated Inhibition of Placental Growth Factor Gene Expression Using Short Interfering Nucleic Acid (siNA)	

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. Section 1.97 - 1.99, the Applicant wishes to make the following references of record in the above-identified application. This Information Disclosure Statement is in compliance with the continuing duty of candor as set forth in 37 C.F.R. Section 1.56. Copies of the cited references are enclosed. All references cited are also listed in the PTO-1449 form enclosed herewith.

The Office has amended the requirement under 37 CFR 1.98 (a)(2)(i) for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. patent applications. See 69 Fed. Reg. 56481. In accordance with this amendment, cited U.S. patents and U.S. patent application publications are not enclosed.

As this Information Disclosure Statement is being submitted after receipt of a foreign search report, a copy of the search report is attached herewith.

In the judgment of the undersigned, portions of the listed references may be material to the Examiner's consideration of the presently pending claims. This statement is not a representation that the listed references have effective dates early enough to be "prior art" within the meaning of 35 U.S.C. Section 102 or Section 103.

Applicants do not believe any fee is due with this submission. If this belief is in error and the Patent Office determines that the fee prescribed in the relevant portion of 37 C.F.R. Section 1.97 is applicable, the undersigned attorney by his signature hereby authorizes any such fee to be debited from Deposit Account 13-2490.

Respectfully submitted,
McDonnell Boehnen Hulbert & Berghoff LLP

Date: October 11, 2005 By: _____
Anita J. Terpstra
Reg. No. 47,132

McDonnell Boehnen Hulbert & Berghoff LLP
300 South Wacker Drive, 32nd Floor
Chicago, IL 60606
Telephone: 312-913-0001
Facsimile: 312-913-0002

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No.	Serial No.
		04-736 (400/134)	10/683,990
		Applicant: McSwiggen et al.	
		Filing Date: October 10, 2003	Group: 1635

OIPE IAP72 OCT 13 2005 PATENT & TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use several sheets if necessary)

U.S. PATENT APPLICATION DOCUMENTS

Examiner Initial		Document Number	Filing Date	Name	Class	Subclass	Publication Date if Appropriate
	*	08/584,040	01/11/96	Pavco et al.			
	*	08/878,640	07/19/97	Usman et al.			
	*	09/205,520	12/03/98	Sullenger et al.			
	*	09/301,511	04/28/99	Beigleman et al.			
	*	09/371,772	08/10/99	Pavco et al.			
	*	09/476,387	12/30/99	Beigelman et al.			
	*	09/708,690	11/07/00	Pavco et al.			
	*	09/740,332	12/18/00	Blatt et al.			
	*	09/800,594	03/06/01	Usman and McSwiggen			
	*	09/870,161	05/29/01	Pavco et al.			
	*	09/877,526	06/08/01	Usman et al.			
	*	09/918,728	07/31/01	Beigelman et al.			
	*	10/138,674	05/03/02	Pavco et al.			
	*	10/417,012	04/16/03	McSwiggen et al.			
	*	10/422,704	04/24/03	McSwiggen et al.			
	*	10/652,791	08/29/03	McSwiggen et al.			

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

McDONNELL BOEHNEN
HULBERT & BERGHOFF LLP
300 SOUTH WACKER DRIVE
CHICAGO, ILLINOIS 60606
TELEPHONE (312) 913-0001

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No.	Serial No.
		04-736 (400/134)	10/683,990
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	**Applicant:** McSwiggen et al.	
		Filing Date: October 10, 2003	**Group:** 1635

	*	10/683,990	10/10/03	McSwiggen et al.			
	*	10/726,236	12/02/03	Lockridge et al.			
	*	10/780,447	02/13/04	Vargeese et al.			
	*	10/826,966	04/16/04	McSwiggen et al.			
	*	60/005,974	10/26/95	Pavco et al.			
	*	60/101,174	09/21/98	Hartmann et al.			
	*	60/292,217	05/18/01	Adamic et al.			
	*	60/306,883	07/20/01	Vargeese et al.			
	*	60/311,865	08/13/01	Vargeese et al.			
	*	60/362,016	03/06/02	Matulic-Adamic et al.			
	*	60/386,782	06/06/02	Beigelman et al.			
	*	US 2002/0137210	08/09/01	Churikov			09/26/02
	*	US 2003/0077829	04/30/02	MacLachlan			04/24/03
	*	US 2003/0190635	07/25/02	McSwiggen et al.			10/09/03
	*	US 2003/0206887	09/16/02	Morrissey et al.			11/06/03

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

McDONNELL BOEHNEN
HULBERT & BERGHOFF LLP
300 SOUTH WACKER DRIVE
CHICAGO, ILLINOIS 60606
TELEPHONE (312) 913-0001

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No.	Serial No.
		04-736 (400/134)	10/683,990
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Applicant:	
	(Use several sheets if necessary)	McSwiggen et al.	
		Filing Date:	Group:
		October 10, 2003	1635

	*	4,987,071	01/22/91	Cech et al.			
	*	5,108,921	04/28/92	Low et al.			
	*	5,270,163	12/14/93	Gold et al.			
	*	5,359,051	10/25/94	Cook et al.			
	*	5,416,016	05/16/95	Low et al.			
	*	5,475,096	12/12/95	Gold et al.			
	*	5,525,468	06/11/96	McSwiggen et al.			
	*	5,589,332	12/31/96	Shih et al.			
	*	5,631,359	05/20/97	Chowrira et al.			
	*	5,741,679	04/21/98	George et al.			
	*	5,807,718	09/15/98	Joyce et al.			
	*	5,834,186	11/10/98	George et al.			
	*	5,849,902	12/15/98	Arrow et al.			
	*	5,871,914	02/16/99	Nathan et al.			
	*	5,968,909	10/19/99	Agrawal et al.			
	*	5,989,912	11/23/99	Arrow et al.			
	*	6,127,173	10/03/00	Eckstein et al.			
	*	6,159,714	12/12/00	Usman et al.			
	*	6,168,778	01/02/01	Janjic et al.			

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

McDONNELL BOEHNEN
HULBERT & BERGHOFF LLP
300 SOUTH WACKER DRIVE
CHICAGO, ILLINOIS 60606
TELEPHONE (312) 913-0001

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No.	Serial No.
		04-736 (400/134)	10/683,990
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Applicant:	
	(Use several sheets if necessary)	McSwiggen et al.	
		Filing Date:	Group:
		October 10, 2003	1635

	*	6,235,886	05/22/01	Manoharan et al.			
	*	6,346,398	02/12/02	Pavco et al.			
	*	6,350,934	02/26/02	Zwick et al.			
	*	6,395,492	05/28/02	Manoharan et al.			
	*	6,566,127	05/20/03	Pavco et al.			

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
	*	0 360 257	02/28/90	EP (Hampel et al.)				
	1.	1 325 955	07/09/03	EP (Klippel-Giese et al.)				
	2.	08208687	08/08/96	JP (Hotoda et al.)				
	*	88/09810	12/15/88	WO (Tullis et al.)				
	*	90/12096	10/18/90	WO (Low et al.)				
	*	93/12569	04/29/93	WO (Draper et al.)				
	*	93/23057	11/25/93	WO (Thompson et al.)				
	*	94/11499	05/26/94	WO (Ullrich et al.)				
	*	94/21679	09/29/94	WO (Kendall et al.)				

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

McDONNELL BOEHNEN
HULBERT & BERGHOFF LLP
300 SOUTH WACKER DRIVE
CHICAGO, ILLINOIS 60606
TELEPHONE (312) 913-0001

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No.	Serial No.
		04-736 (400/134)	10/683,990
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Applicant:	
	(Use several sheets if necessary)	McSwiggen et al.	
		Filing Date:	Group:
		October 10, 2003	1635

	*	94/21791	09/29/94	WO (Bergmann et al.)				
	*	95/04142	02/09/95	WO (Robinson et al.)				
	*	95/04818	02/16/95	WO (Draper et al.)				
	*	95/11304	04/27/95	WO (Usman et al.)				
	*	95/13380	05/18/95	WO (Draper et al.)				
	*	95/21868	08/17/95	WO (Rockwell and Goldstein)				
	*	95/23225	08/31/95	WO (Stinchcomb et al.)				
	*	96/22689	08/01/96	WO (Pyle et al.)				
	*	97/00957	01/09/97	WO (Patterson-Winston et al.)				
	*	97/15662	05/01/97	WO (Pavco et al.)				
	3.	97/21808	06/19/97	WO (Robinson)				
	*	98/27104	06/25/98	WO (Breaker et al.)				
	*	98/28317	07/02/98	WO (Matulic-Adamic et al)				
	*	98/43993	10/08/98	WO (Breaker et al.)				
	*	98/58058	12/23/98	WO (Ludwig & Sproat)				
	*	99/04819	02/04/99	WO (Klimuk)				
	*	99/05094	02/04/99	WO (Beigelman et al.)				
	*	99/16871	04/08/99	WO (Eckstein et al.)				
	*	99/17120	04/08/99	WO (Davis and Bishop)				

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

McDONNELL BOEHNEN
HULBERT & BERGHOFF LLP
300 SOUTH WACKER DRIVE
CHICAGO, ILLINOIS 60606
TELEPHONE (312) 913-0001

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No.	Serial No.
		04-736 (400/134)	10/683,990
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Applicant:	
	(Use several sheets if necessary)	McSwiggen et al.	
		Filing Date:	Group:
		October 10, 2003	1635

	*	99/29842	06/17/99	WO (Sullenger et al.)				
	*	99/55857	11/04/99	WO (Beigelman et al.)				
	*	99/63116	12/09/99	WO (Storella et al.)				
	*	99/66063	12/23/99	WO (Manoharan et al.)				
	4.	00/03683	01/27/00	WO (Boey et al.)				
	*	00/24931	05/04/00	WO (Nathan and Ellington)				
	*	00/26226	05/11/00	WO (Breaker et al.)				
	*	00/73416	12/07/00	WO (Labarbera et al.)				
	*	01/32920	05/10/01	WO (Pappa)				
	*	01/96584	12/20/01	WO (Mushegian et al.)				
	5.	01/097850	12/27/01	WO (Siemeister et al.)				
	6.	02/07747	01/31/02	WO (King)				
	7.	02/10378	02/07/02	WO (Cowsert et al.)				
	8.	02/087541	11/07/02	WO (MacLachlan)				
	*	02/094185 (PCT/US02/15876)	11/28/02	WO (Beigelman et al.)				
	9.	03/063904	07/07/03	WO (Koninckx et al.)				
	10.	03/068797	08/21/03	WO (Rossi et al.)				
	11.	03/070887	08/28/03	WO (McSwiggen et al.)				
	12.	03/070896	08/28/03	WO (McSwiggen et al.)				

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

McDONNELL BOEHNEN
HULBERT & BERGHOFF LLP
300 SOUTH WACKER DRIVE
CHICAGO, ILLINOIS 60606
TELEPHONE (312) 913-0001

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No.	Serial No.
		04-736 (400/134)	10/683,990
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	**Applicant:** McSwiggen et al.	
		Filing Date: October 10, 2003	**Group:** 1635

	13.	03/070910	08/28/03	WO (McSwiggen et al.)				
	14.	03/080638	10/02/03	WO (Lacasse et al.)				
	15.	04/009769	01/29/04	WO (Tolentino et al.)				
	16.	04/043977	05/27/04	WO (Prakush et al.)				
	17.	04/072261	08/26/04	WO (Li et al.)				
	*	PCT/US02/17674	05/29/02	WO (Pavco et al.)				
	*	PCT/US03/05022	02/20/03	WO (McSwiggen et al.)				
	18.	PCT/US04/13456	04/30/04	WO (Vargeese et al.)				
	19.	PCT/US04/16390	05/24/04	WO (McSwiggen et al.)				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).

	*	Abramovitz et al., "Catalytic Role of 2'-Hydroxyl Groups Within a Group II Intron Active Site," Science 271:1410-1413 (1996)
	*	Aiello et al., "Suppression of Retinal Neovascularization *in vivo* by Inhibition of Vascular Endothelial Growth Factor (VEGF) Using Soluble VEGF-Receptor Chimeric Proteins," Proc. Natl. Acad. Sci. USA 92: 10457-10461 (1995)
	20.	Anderson et al., "Bispecific Short Hairpin siRNA Constructs Targeted to CD4, CXCR4, and CCR5 Confer HIV-1 Resistance," Oligonucleotides, 13:303-312 (2003)
	*	Antopolsky et al., "Peptide-Oligonucleotide Phosphorothioate Conjugates with Membrane Translocation and Nuclear Localization Properties," Bioconjugate Chem. 10:598-606 (1999)
	*	Arap et al., "Cancer Treatment by Targeted Drug Delivery to Tumor Vasculature in a Mouse Model," Science 279:377-380 (1998)

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

McDONNELL BOEHNEN
HULBERT & BERGHOFF LLP
300 SOUTH WACKER DRIVE
CHICAGO, ILLINOIS 60606
TELEPHONE (312) 913-0001

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No.	Serial No.
		04-736 (400/134)	10/683,990
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicant: McSwiggen et al.	
		Filing Date: October 10, 2003	Group: 1635

	*	Banerjee and Turner, "The Time Dependence of Chemical Modification Reveals Slow Steps in the Folding of a Group I Ribozyme," Biochemistry 34:6504-6512 (1995)
	*	Bartel and Szostak, "Isolation of New Ribozymes from a Large Pool of Random Sequences," Science 261:1411-1418 (1993)
	21.	Bayard et al., "Increased stability and antiviral activity of 2'-O-phosphoglyceryl derivatives of (2'-5')oligo(adenylate)," *Eur. J. Biochem.*, 142(29):291-298 (1984)
	*	Beaudry and Joyce, "Directed Evolution of an RNA Enzyme," Science 257:635-641 (1992)
	*	Berzal-Herranz et al., "Essential nucleotide sequences and secondary structure elements of the hairpin ribozyme," EBMO J. 12:2567-2574 (1993)
	*	Berzal-Herranz et al., "In vitro selection of active hairpin ribozymes by sequential RNA-catalyzed clevage and ligation reactions," Genes & Development 6:129-134 (1992)
	*	Bevilacqua et al., "A Mechanistic Framework for the Second Step of Splicing Catalyzed by the *Tetrahymena* Ribozyme," Biochemistry 35:648-568 (1996)
	*	Blesch, "Delivery of Neurotrophic Factors to Neuronal Targets: Toward Gene Therapy in the CNS," Drug News & Perspectives 13:269-280 (2000)
	*	Bongartz et al., "Improved biological activity of antisense oligonucleotides conjugated to a fusogenic peptide," *Nucleic Acids Research* 22:4681-4688 (1994)
	*	Bonora et al., "Biological Properties of Antisense Oligonucleotides Conjugated to Different High-Molecular Mass Poly(ethylen glycols)," Nucleosides & Nucleotides 18:1723-1725 (1999)
	*	Bonora et al., "Synthesis and Characterization of High-Molecular Mass Polyethylene Glycol-Conjugated Oligonucleotides," Bioconjugate Chem. 8:793-797 (1997)
	*	Breaker and Joyce, "Inventing and improving ribozyme function: rational design versus iterative selection methods," TIBTECH 12:268-275 (1994)
	*	Breaker et al., "A DNA enzyme with Mg^2-dependent RNA phosphoesterase activity," Chemistry & Biology 2(10):655-660 (1995)

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

McDONNELL BOEHNEN
HULBERT & BERGHOFF LLP
300 SOUTH WACKER DRIVE
CHICAGO, ILLINOIS 60606
TELEPHONE (312) 913-0001

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No.	Serial No.
		04-736 (400/134)	10/683,990
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Applicant:	
	(Use several sheets if necessary)	McSwiggen et al.	
		Filing Date:	Group:
		October 10, 2003	1635

	*	Breaker, "Are engineered proteins getting competition from RNA?" Current Opinion in Biotechnology 7:442-448 (1996)
	*	Breaker, "Catalytic DNA: in training and seeking employment," *Nature Biotechnology* 17:422-423 (1999)
	*	Brogniez et al., "Fluorescence of Experimented Endometriosis in Rabbits, Using Tamoxifen-eosin Association," Human Reproduction 10:927-931 (1995)
	*	Buckwold et al., "Effects of a Naturally Occurring Mutation in the Hepatitis B Virus Basal Core Promoter on Precore Cene Expression and Viral Replication," *Journal of Virology,* 5845-5851 (1996)
	*	Carter, "Adeno-Associated Virus Vectors," Curr Opi. Biotech. 3:533-539 (1992)
	*	Cebon et al., "New DNA Modification Strategies Involving Oxime Formation," Aust. J. Chem. 53:333-339 (2000)
	*	Cech, "Ribozymes and Their Medical Implications," JAMA 260:3030-3034 (1988)
	*	Chaloin et al., "Design of Carrier Peptide-Oligonucleotide Conjugates With Rapid Membrane Translocation and Nuclear Localization Properties," BBRC 243:601-608 (1998)
	*	Chartrand et al., "An oligodeoxyribonucleotide that supports catalytic activity in the hammerhead ribozyme domain," Nucleic Acids Research 23(20):4092-4096 (1995)
	*	Chowrira et al., "Novel guanosine requirement for catalysis by the hairpin ribozyme," Nature 354:320-322 (1991)
	*	Christoffersen and Marr, "Riobozymes as Human Therapeutic Agents," J. Med. Chem. 38:2023-2037 (1995) (also referred to as Christofferson and Marr)
	*	Christoffersen et al., "Application of computational techologies to ribozyme biotechnology products," Journal of Molecular Structure (Theochem) 311:273-284 (1994) (maybe referred to as Christofferson)

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

McDONNELL BOEHNEN
HULBERT & BERGHOFF LLP
300 SOUTH WACKER DRIVE
CHICAGO, ILLINOIS 60606
TELEPHONE (312) 913-0001

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No.	Serial No.
		04-736 (400/134)	10/683,990
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant: McSwiggen et al.	
		Filing Date: October 10, 2003	Group: 1635

	*	Chun et al., "Effect of infusion of vasoactive intestinal peptide (VIP)-antisense oligodeoxynucleotide into the third cerebral ventricle above the hypothalamic cuprachiasmatic nucleus on the hyperglycemia caused by intracranial injection of 2-deoxy-D-glucose in rats," *Neuroscience Letters* 257:135-138 (1998)
	*	Cole et al., "Activation of RNase L by 2',5'-Oligoadenylates," The Journal of Biological Chemistry, 272:31, 19187-19192 (1997)
	*	Collins and Olive, "Reaction Conditions and Kinetics of Self-Cleavage of a Ribozyme Derived From *Neurospora* VS RNA," Biochemistry 32:2795-2799 (1993)
	*	Crooke, "Advances in Understanding the Pharmacological Properties of Antisense Oligonucleotides," Advances in Pharmacology 40:1-49 (1997)
	*	Crooke, "Antisense Therapeutics," Biotechnology and Genetic Engineering Reviews 15:121-157 (1998)
	*	Crooke, "Progress in Antisense Technology: The End of the Beginning," Methods in Enzymology 313:3-45 (1999)
	*	Cummings and Metcalf, "Effect of Surgically Induced Endometriosis on Pregnancy and Effect of Pregnancy and Lactation on Endometriosis in Mice[1]" P.S.E.B.M. 212:332-337 (1996)
	*	Cummings et al., "Promotion of Endometriosis by 2,3, 7, 8-Tetrachlorodibenzo-*p*-dioxin in Rats and Mice: Time-Dose Dependence and Species Comparison[1,2]," Toxicology and Applied Pharmacology 138:131-139 (1996)
	*	d'Aldin et al., "Antisense oligonucleotides to the GluR2 AMPA receptor subunit modify excitatory synaptic transmission in vivo," *Molecular Brain Research* 55:151-164 (1998)
	*	D'Hooghe et al., "The Cycle Pregnancy Rate is Normal in Baboons with Stage I Endometriosis but Decreased in Primates with Stage II and Stage III-IV Disease," Fertility and Sterility 66:809-813 (1996)

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

McDONNELL BOEHNEN
HULBERT & BERGHOFF LLP
300 SOUTH WACKER DRIVE
CHICAGO, ILLINOIS 60606
TELEPHONE (312) 913-0001

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No.	Serial No.
		04-736 (400/134)	10/683,990
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	**Applicant:** McSwiggen et al.	
		Filing Date: October 10, 2003	**Group:** 1635

	*	Daniels et al., "Two Competing Pathways for Self-splicing by Group II Introns: A Quantitative Analysis of *in Vitro* Reaction Rates and Products," J. Mol. Biol. 256:31-49 (1996)
	*	Defrancq and Lhomme, "Use of an Aminooxy Linker for the Functionalization of Oligodeoxyribonucleotides," Bioorganic & Medicinal Chem. Lett. 11:931-933 (2001)
	*	Delihas et al., "Natural antisense RNA/target RNA interactions: Possible models for antisense oligonucleotide drug design," Nature Biotechnology 15:751-753 (1997)
	*	Donnez et al., "Vascular Endothelial Growth Factor (VEGF) in Endometriosis," Human Reproduction 13:1686-1690 (1998)
	*	Dreyfus, "Restriction Ribozymes?" Einstein Quarterly Journal of Biology and Medicine 6:92-93 (1988)
	*	Dryden et al., "The lack of specificity of neuropeptide Y (NPY) antisense oligodeoxynucleotides administered intracerebroventricularly in inhibiting food intake and NPY gene expression in the rat hypothalamus," *Journal of Endocrinology* 157:169-175 (1998)
	*	Duval-Valentin, "Specific inhibition of transcription by triple helix-forming oligonucleotides," Proc. Natl. Acad. Sci. USA 89:504-508 (1992)
	*	Egholm et al., "PNA hybridizes to complementary oligonucleotides obeying the Watson-Crick hydrogen-bonding rules," Nature 365:566-568 (1993)
	*	Fasciani et al., "High Concentrations of the Vascular Endothelial Growth Factor and Interleukin-8 in Ovarian Endometriomata," Molecular Human Reproduction 6:50-54 (2000)
	*	Feldstein et al., "Two sequences participating in the autolytic processing of satellite tobacco ringspot virus complementary RNA," Gene 82:53-61 (1989)
	*	Ferrara, "Vascular Endothelial Growth Factor," *Trends Cardiovasc Med* 3:244-250 (1993)

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

McDONNELL BOEHNEN
HULBERT & BERGHOFF LLP
300 SOUTH WACKER DRIVE
CHICAGO, ILLINOIS 60606
TELEPHONE (312) 913-0001

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No.	Serial No.
		04-736 (400/134)	10/683,990
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant: McSwiggen et al.	
		Filing Date: October 10, 2003	Group: 1635

	*	Filion and Phillips, "Toxicity and immunomodulatory activity of liposomal vectors formulated with cationic lipids toward immune effector cells," *Biochimica et Biophysica Acta* 1329:345-356 (1997)
	*	Findeis, "Stepwise Synthesis of a GalNAc-containing Cluster Glycoside Ligand of the Asialoglycoprotein Receptor," Int. J. Peptide Protein Res. 43:477-485 (1994)
	*	Folkman and Shing, "Angiogenesis," J. Biol. Chem. 267:10931-10934 (1992)
	*	Folkman, "What is the Evidence that Tumors are Angiogenesis Dependent?" Journal of the National Cancer Institute 82:4-6 (1990)
	*	Fong *et al.*, "Role of the Flt-1 Receptor Tyrosine Kinase in Regulating the Assembly of Vascular Endothelium," 1995 *Nature* 376, 66 **Corrected from specification**
	*	Forster and Altman, "External Guide Sequences for an RNA Enzyme," Science 249:783-786 (1990)
	*	Fox, "Targeting DNA with Triplexes," *Current Medicinal Chemistry* 7:17-37 (2000)
	*	Genbank Accession No. AB020693
	22.	Genbank Accession No. AC006530
	*	Genbank Accession No. AF037412
	*	Genbank Accession No. AF100308.1
	*	Genbank Accession No. AJ430458
	23.	Genbank Accession No. BC001422
	24.	Genbank Accession No. BC007255
	25.	Genbank Accession No. BC007789
	26.	Genbank Accession No. BT007182

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

McDONNELL BOEHNEN
HULBERT & BERGHOFF LLP
300 SOUTH WACKER DRIVE
CHICAGO, ILLINOIS 60606
TELEPHONE (312) 913-0001

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No.	Serial No.
		04-736 (400/134)	10/683,990
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Applicant:	
	(Use several sheets if necessary)	McSwiggen et al.	
		Filing Date:	Group:
		October 10, 2003	1635

	27.	Genbank Accession No. BT008273
	28.	Genbank Accession No. BX248389
	*	Genbank Accession No. D00239
	*	Genbank Accession No. D11168
	*	Genbank Accession No. D50483.1
	*	Genbank Accession No. K02121
	*	Genbank Accession No. L24917
	*	Genbank Accession No. L38318
	*	Genbank Accession No. M16248
	*	Genbank Accession No. M31724
	*	Genbank Accession No. NC_001345
	*	Genbank Accession No. NC_001347
	*	Genbank Accession No. NC_001353
	*	Genbank Accession No. NC_001563
	*	Genbank Accession No. NC_001781
	*	Genbank Accession No. NC_004718
	*	Genbank Accession No. NM_001285
	*	Genbank Accession No. NM_001982
	*	Genbank Accession No. NM_002592.1
	29.	Genbank Accession No. NM_002632

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

McDONNELL BOEHNEN
HULBERT & BERGHOFF LLP
300 SOUTH WACKER DRIVE
CHICAGO, ILLINOIS 60606
TELEPHONE (312) 913-0001

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No.	Serial No.
		04-736 (400/134)	10/683,990
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Applicant:	
	(Use several sheets if necessary)	McSwiggen et al.	
		Filing Date:	Group:
		October 10, 2003	1635

	*	Genbank Accession No. NM_002667
	*	Genbank Accession No. NM_002737
	*	Genbank Accession No. NM_003219
	*	Genbank Accession No. NM_004283
	*	Genbank Accession No. NM_004448
	*	Genbank Accession No. NM_005228
	*	Genbank Accession No. NM_005235
	30.	Genbank Accession No. S72960
	*	Genbank Accession No. S82227
	*	Genbank Accession No. U51188
	*	Genbank Accession No. U86046
	*	Genbank Accession No. X01087
	*	Genbank Accession No. X02316
	*	Genbank Accession No. X07203
	*	Genbank Accession No. X51602
	31.	Genbank Accession No. X54936
	*	Genbank Accession No. X60667
	*	Genbank Accession No. XM_015620

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

McDONNELL BOEHNEN
HULBERT & BERGHOFF LLP
300 SOUTH WACKER DRIVE
CHICAGO, ILLINOIS 60606
TELEPHONE (312) 913-0001

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No.	Serial No.
		04-736 (400/134)	10/683,990
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicant: McSwiggen et al.	
		Filing Date: October 10, 2003	Group: 1635

	*	Genbank Accession No. XM_033884
	*	Genbank Accession No. XM_067723
	*	Ghirnikar et al., "Chemokine inhibition in rat stab would brain injury using antisense oligodeoxynucleotides," Neuroscience Letters 247:21-24 (1998)
	*	Gitay-Goren et al., "The Binding of Vascular Endothelial Growth Factor to Its Receptors Is Dependent on Cell Surface-associated Heparin-like Molecules," *The Journal of Biological Chemistry* 267:6093-6098 (1992)
	*	Godwin et al., "The Synthesis of Biologically Active Pteroyloligo-γ-$_L$-Glutamates (Folic Acid Conjugates)," The Journal of Biological Chemistry 247:2266-2271 (1972)
	*	Gold, "Axonal Regeneration of Sensory Nerves is Delayed by Continuous Intrathecal Infusion of Nerve Growth Factor," *Neuroscience* 76:1153-1158 (1997)
	*	Grasby et al., "Purine Functional Groups in Essential Residues of the Hairpin Ribozyme Required for Catalytic Cleavage of RNA," Biochemistry 34:4068-4076 (1995)
	*	Griffin et al., "Group II intron ribozymes that cleave DNA and RNA linkages with similar efficiency, and lack contacts with substrate 2'-hydroxyl groups," Chemistry & Biology 2:761-770 (1995)
	*	Groothuis and Levy, "The entry of antiviral and antiretroviral drugs into the central nervous system," Journal of NeuroVirology 3:387-400 (1997)
	*	Guerrier-Takada et al., "Metal Ion Requirements and Other Aspects of the Reaction Catalyzed by M1 RNA, the RNA Subunit of Ribonuclease P from *Escherichia coli*," Biochemistry 25:1509-1515 (1986)
	*	Guerrier-Takada et al., "The RNA Moiety of Ribonuclease P Is the Catalytic Subunit of the Enzyme," Cell 35:849-857 (1983)
	*	Guo and Collins, "Efficent *trans*-cleavage of a stem-loop RNA substrate by a ribozyme derived from *Neurospora* VS RNA," EMBO J. 14:368-376 (1995)

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

McDONNELL BOEHNEN
HULBERT & BERGHOFF LLP
300 SOUTH WACKER DRIVE
CHICAGO, ILLINOIS 60606
TELEPHONE (312) 913-0001

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No.	Serial No.
		04-736 (400/134)	10/683,990
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Applicant:	
	(Use several sheets if necessary)	McSwiggen et al.	
		Filing Date:	Group:
		October 10, 2003	1635

	*	Habus et al., "A Mild and Efficient Solid-Support Synthesis of Novel Oligonucleotide Conjugates," Bioconjugate Chem. 9:283-291 (1998)
	*	Hagihara et al., "Widespread gene transfection into the central nervous system of primates," Gene Therapy 7:759-763 (2000)
	*	Hammann et al., "Length Variation of Helix III in a Hammerhead Ribozyme and Its Influence on Cleavage Activity," *Antisense & Nucleic Acid Drug Development* 9:25-31 (1999)
	*	Hampel and Tritz, "RNA Catalytic Properties of the Minimum (-)sTRSV Sequence," Biochemistry 28:4929-4933 (1989)
	*	Hampel et al., "'Hairpin' Catalytic RNA Model: Evidence for Helices and Sequence Requirement for Substrate RNA," Nucleic Acids Research 18:299-304 (1990)
	*	Harris et al., "Identification of phosphates involved in catalysis by the ribozyme RNase P RNA," RNA 1:210-218 (1995)
	*	Hartmann et al., "Spontaneous and Cationic Lipid-Mediated Uptake of Antisense Oligonucleotides in Human Monocytes and Lymphocytes," The Journal of Pharmacology and Experimental Therapeutics 285:920-928 (1998)
	*	Haseloff and Gerlach, "Sequences required for self-catalysed cleavage of the satellite RNA of tobacco ringspot virus," Gene 82:43-52 (1989)
	*	Haseloff and Gerlach, "Simple RNA Enzymes with New and Highly Specific Endoribonuclease Activities," Nature 334:585-591 (1988)
	*	Hegg et al., "Kinetics and Thermodynamics of Intermolecular Catalysis by Hairpin Ribozymes," Biochemistry 34:15813-15828 (1995)
	*	Herrlinger et al., "HSV-1 Vectors for Gene Therapy of Experimental CNS Tumors," Methods Mol. Med. 35:287-312 (2000)
	*	Herschlag and Cech, "Catalysis of RNA Cleavage by the *Tetrahymena thermophila* Ribozyme 1. Kinetic Description of the Reaction of an RNA Substrate Complementary to the Active Site," Biochemistry 29:10159-10171 (1990)

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

McDONNELL BOEHNEN
HULBERT & BERGHOFF LLP
300 SOUTH WACKER DRIVE
CHICAGO, ILLINOIS 60606
TELEPHONE (312) 913-0001

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No.	Serial No.
		04-736 (400/134)	10/683,990
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Applicant:	
	(Use several sheets if necessary)	McSwiggen et al.	
		Filing Date:	Group:
		October 10, 2003	1635

	*	Herschlag and Cech, "Catalysis of RNA Cleavage by the *Tetrahymena thermophila* Ribozyme. 2. Kinetic Description of the Reaction of an RNA Substrate That Forms a Mismatch at the Active Site," Biochemistry 29:10172-10180 (1990)
	*	Hertel et al., "A Kinetic Thermodynamic Framework for the Hammerhead Ribozyme Reaction," Biochemistry 33:3374-3385 (1994)
	*	Hertel et al., "Numbering System for the Hammerhead," Nucleic Acids Research 20:3252 (1992)
	*	Ho et al., "Antisense Oligonucleotides for Target Validation in the CNS," Current Opinion in Molecular Therapeutics 1:336-343 (1999)
	*	Hudson et al., "Cellular Delivery of Hammerhead Ribozymes Conjugated to a Transferrin Receptor Antibody," Int'l Jour. of Pharmaceutics 182:49-58 (1999)
	*	International Search Report for PCT/US02/17674, Filed May 29, 2002
	32.	International Search Report for PCT/US03/05022 mailed January 6, 2005
	33.	International Search Report for PCT/US2004/016390 mailed March 31, 2005
n	34.	International Search Report for PCT/US2004/027403 mailed July 12, 2005
	35.	International Search Report for PCT/US2004/030488 mailed January 12, 2005
	*	International Search Report for PCT/US96/17480, Filed October 25, 1996
	*	Ishizaka et al., "Isolation of Active Ribozymes from an RNA Pool of Random Sequences Using an Anchored Substrate RNA," Biochemical and Biophysical Research Communication 214(2):403-409 (1995)
	*	Jaeger et al., "Improved Predictions of Secondary Structures for RNA," Proc. Natl. Acad. Sci. USA 86:7706-7710 (1989)
	*	Jarvis et al., "Optimizing the Cell Efficacy of Synthetic Ribozymes," Journal of Biological Chemistry 271:29107-29112 (1996)

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

McDONNELL BOEHNEN
HULBERT & BERGHOFF LLP
300 SOUTH WACKER DRIVE
CHICAGO, ILLINOIS 60606
TELEPHONE (312) 913-0001

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No.	Serial No.
		04-736 (400/134)	10/683,990
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Applicant:	
	(Use several sheets if necessary)	McSwiggen et al.	
		Filing Date:	Group:
		October 10, 2003	1635

	*	Jaschke et al., "Synthesis and Properties of Oligodeoxyribonuclotide-polyethylene Glycol Conjugates," Nucleic Acids Research 22:4810-4817 (1994)
	*	Jaschke, "Oligonucleotide-Poly(ethylene glycol) Conjugates: Synthesis, Properties, and Application," American Chemical Society 680:265-283 (1997)
	*	Jeffries and Symons, "A Catalytic 13-mer Ribozyme," Nucleic Acids Research 17:1371-1377 (1989) (also referred to as Jefferies)
	*	Jellinek et al., "Inhibitions of Receptor Binding by High-Affinity RNA Ligands to Vascular Endothelial Growth Factor," Biochemistry 33:10450-10456 (1994)
	36.	Jen et al., "Suppression of gene Expression by Targeted Disruption of Messenger RNA: Available Options and Current Strategies," Stem Cells, 18:307-319 (2000)
	*	Joseph et al., "Substrate selection rules for the hairpin ribozyme determined by in vitro selection, mutation, and analysis of mismatched substrates," Genes & Development 7:130-138 (1993)
	*	Joyce et al., "Amplification, mutation and selection of catalytic RNA," Gene 82:83-87 (1989)
	*	Joyce, "Directed Molecular Evolution," Scientific American 267:90-97 (1992)
	*	Kim and Cech, "Three-dimensional model of the active site of the self-splicing rRNA precursor of *Tetrahymena*," Proc. Natl. Acad. Sci. USA 84:8788-8792 (1987)
	*	Knitt et al., "ph Dependencies of the *Tetrahymena* Ribozyme Reveal an Unconvential Origin of an Apparent pK_a," Biochemistry 35:1560-1570 (1996)
	*	Kore, et al., "Sequence specificity of the hammerhead ribozyme revisistsed; the NIH rule," Nucleic Acids Research, 26(18):4116-4120 (1998).
	*	Kronenwett et al., "Oligodeoxyribonucleotide Uptake in Primary Human Hematopoietic Cells is Enhanced by Cationic Lipids and Depends on the Hematopoietic Cell Subset," Blood 91:852-862 (1998)
	*	Kumar and Ellington, "Artificial evolution and natural ribozymes," FASEB J. 9:1183-1195 (1995)

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

McDONNELL BOEHNEN
HULBERT & BERGHOFF LLP
300 SOUTH WACKER DRIVE
CHICAGO, ILLINOIS 60606
TELEPHONE (312) 913-0001

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No.	Serial No.
		04-736 (400/134)	10/683,990
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant: McSwiggen et al.	
		Filing Date: October 10, 2003	Group: 1635

	*	Kunath et al., "The structure of PEG-modified poly(ethylene imines) influences biodistribution and pharmacokinetics of their complexes with NF-kappaB decoy in mice.," Medline (Pharm Res.) 19(6): 810-817 (6/1/2002)
	37.	Kuwabara et al., "A C. elegans patched gene, ptc-1, functions in germ-line cytokinesis," *Genes and Development,* 14(15):1933-1944 (2000)
	*	Kuwabara et al., "Allosterically Controllable Ribozymes with Biosensor Functions," Current Opinion in Chem. Biol. 4:669-677 (2000)
	*	Lee et al., "Enhancing the Catalytic Repertoire of Nucleic Acids: A Systematic Study of Linker Length and Rigidity," Nucleic Acids Research 29:1565-1573 (2001)
	38.	Leifer et al., "Heterogeneity in the Human Response to Immunostimulatory CpG Oligodeoxynucleotides," *Journal of Immunotherapy,* 26(4):313-319 (2003)
	*	Lendlein et al., "Biodegradable, Elastic Shape-Memory Polymers for Potential Biomedical Applications," *Science,* 296, 1673-1676 (2002)
	*	Li and Altman, "Cleavage by RNase P of gene N mRNA reduces bacteriophage λ burst size," Nucleic Acids Research 24:835-842 (1996)
	*	Li et al., "Thermodynamic and Activation Parameters for Binding of a Pyrene-Labeled Substrate by the *Tetrahymena* Ribozyme: Docking is Not Diffusion-Controlled and is Driven by a Favorable Entropy Change," Biochemistry 34:14394-14399 (1995)
	*	Lichner et al., "Double-stranded RNA-binding proteins could suppress RNA interference-mediated antiviral defences," *Journal of General Virology,* 84, 975-980 (2003)
	*	Lieber et al., "Stable High-Level Gene Expression in Mammalian Cells by T7 Phage RNA Polymerase," Methods Enzymol. 217:47-66 (1993)
	*	Lieber et al., "Stable High-Level Gene Expression in Mammalian Cells by T7 Phage RNA Polymerase," Methods Enzymol. 217:47-66 (1993)
	*	Limbach et al., "Summary: the modified nucleosides of RNA," Nucleic Acids Research 22(12):2183-2196 (1994)

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

McDONNELL BOEHNEN
HULBERT & BERGHOFF LLP
300 SOUTH WACKER DRIVE
CHICAGO, ILLINOIS 60606
TELEPHONE (312) 913-0001

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No.	Serial No.
		04-736 (400/134)	10/683,990
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Applicant:	
	(Use several sheets if necessary)	McSwiggen et al.	
		Filing Date:	Group:
		October 10, 2003	1635

	*	Lin and Matteucci, "A Cytosine Analogue Capable of Clamp-Like Binding to a Guanine in Helical Nucleic Acid," *J. Am. Chem. Soc.* 120:8531-8532 (1998)
	*	Lin et al., "A Novel mRNA-cRNA Interference Phenomenon for Silencing bcl-2 Expression in Human LNCaP Cells," Biochemical and Biophysical Research Communications, 281, 639-644 (2001)
	*	Lin et al., "Policing rogue genes," Nature, 402, 128-129 (1999)
	*	Lisziewicz et al., "Inhibition of Human Immunodeficiency Virus Type 1 Replication by Regulated Expression of a Polymeric Tat Activation Response RNA Decoy as a Strategy for Gene Therapy in AIDS," Proc. Natl. Acad. Sci. U.S.A. 90:8000-8004 (1993)
	*	Liu et al., "Cationic Liposome-mediated Intravenous Gene Delivery," J. Biol. Chem. 270(42):24864-24870 (1995)
	*	Long and Uhlenbeck, "Kinetic characterization of intramolecular and intermolecular hammerhead RNAs with stem II deletions," Proc. Natl. Acad. Sci. USA 91:6977-6981 (1994)
	39.	Lu et al., "Tumor Inhibition By RNAi-Mediated VEGF an VEGFR2 Down Regulation in Xenograft Models," *Cancer Gene Therapy,* 10, Suppl. 1, S4-S5 (2003)
	*	Ma and Wei, "Enhanced Delivery of Synthetic Oligonucleotides to Human Leukaemic Cells by Liposomes and Immunoliposomes," Leukemia Research 20:925-930 (1996)
	*	Maher et al., "Kinetic Analysis of Oligodeoxyribonucleotide-Directed Triple-Helix Formation on DNA," *Biochemistry* 29:8820-8826 (1990)
	*	McKay, "Structure and function of the hammerhead ribozyme: an unfinished story," RNA 2:395-403 (1996)
	*	McLaren, "Vascular Endothelial Growth Factor and Endometriotic Angiogenesis," Human Reproduction Update 6:45-55 (2000)
	*	Michel and Westhof, "Slippery substratrates," Nat. Struct. Biol. 1:5-7 (1994)

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

McDONNELL BOEHNEN
HULBERT & BERGHOFF LLP
300 SOUTH WACKER DRIVE
CHICAGO, ILLINOIS 60606
TELEPHONE (312) 913-0001

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No.	Serial No.
		04-736 (400/134)	10/683,990
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant: McSwiggen et al.	
		Filing Date: October 10, 2003	Group: 1635

	*	Michel et al., "Structure and Activities of Group II Introns," Annu. Rev. Biochem. 64:435-461 (1995)
	*	Michels and Pyle, "Conversion of a Group II Intron into a New Multiple-Turnover Ribozyme that Selectively Cleaves Oligonucleotides: Elucidation of Reaction Mechanism and Structure/Function Relationships," Biochemistry 34:2965-2977 (1995)
	*	Millauer, "High Affintiy VEGF Binding and Developmental Expression Suggest Flk-1 as a Major Regulator of Vasculogenesis and Angiogenesis," Cell 72:835-846 (1993)
	*	Milligan and Uhlenbeck, "Synthesis of Small RNAs Using T7 RNA Polymerase," Methods Enzymol. 180:51-62 (1989)
	*	Milner et al., "Selecting effective antisense reagents on combinatorial oligonucleotide arrays," *Nature Biotechnology* 15:537-541 (1997)
	*	Mitra et al., "A mammalian 2-5A system functions as an antiviral pathway in transgenic plants," Proc. Natl. Acad. Sci. USA 93:6780-6785 (1996)
	*	Mohr et al., "A tyrosyl-tRNA synthetase can function similarly to an RNA structure in the *Tetrahymena* ribozyme," Nature 370:147-150 (1994)
	*	Mori et al., "Inhibition of Chorodial Neovascularization by Intravenous Injection of Adenoviral Vectors Expressing Secretable Endostatin," American Journal of Pathology, 159(1), 313-320 (2001)
	*	Morris et al., "A New Peptide Vector for Efficient Delivery of Oligonucleotides into Mammalian Cells," Nucleic Acids Research 25:2730-2736 (1997)
	*	Mukhopadhyay et al., "Antisense Regulation of Oncogenes in Human Cancer," Critical Reviews in Oncogenesis 7:151-190 (1996)
	*	Nakamaye and Eckstein, "AUA-Cleaving Hammerhead Ribozymes: Attempted Selection for Improved Cleavage," Biochemistry 33:1271-1277 (1994)
	*	Nathans and Smith, "Restriction Endonucleases in the Analysis and Restructuring of DNA Molecules," Ann. Rev. Biochem. 44:273-293 (1975)

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

McDONNELL BOEHNEN
HULBERT & BERGHOFF LLP
300 SOUTH WACKER DRIVE
CHICAGO, ILLINOIS 60606
TELEPHONE (312) 913-0001

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No.	Serial No.
		04-736 (400/134)	10/683,990
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Applicant:	
	(Use several sheets if necessary)	McSwiggen et al.	
		Filing Date:	Group:
		October 10, 2003	1635

	*	Neufeld et al., "Vascular Endothelial Growth Factor and Its Receptors," *Progress in Growth Factor Research* 5:89-97 (1994)
	*	Nomura et al., "Development of an Efficient Intermediate, α-[2-(Trimethylsilyl) ethoxy]-2-*N*-[2-trimethylsilyl)ethoxycarbonyl]folic Acid, for the Synthesis of Folate (γ)-Conjugates, and Its Application to the Synthesis of Folate-Nucleoside Conjugates," J. Org. Chem. 65:5016-5021 (2000)
	*	Orgel, "Selection *in vitro*," Proc. R. Soc. London B. 205:435-442 (1979)
	*	Pan et al., "Probing of tertiary interactions in RNA: 2'-Hydroxyl-base contacts between the Rnase P and pre-tRNA," Proc. Natl. Acad. Sci. USA 92:12510-12514 (1995)
	*	Parry *et al.* 1999. "Bioactivity of anti-angiogenic ribozymes targeting *Flt*-1 and *KDR* mRNA," Nucleic Acid Res. 27:2569-77.
	*	Peel and Klein, "Adeno-associated virus vectors: activity and applications in the CNS," Journal of Neuroscience Methods 98:95-104 (2000)
	*	Perrotta and Been, "A pseudoknot-like structure required for efficeint self-cleavage of hepatitis delta virus RNA," Nature 350:434-436 (1991)
	*	Perrotta and Been, "Cleavage of Oligoribonucleotides by a Ribozyme Derived from the Hepatitis δ Virus RNA Sequence," Biochemistry 31:16-21 (1992)
	*	Peterson et al., "Future Prospects of Gene Therapy for Treating CNS Diseases," Central Nervous System Diseases Chapter 24:485-508 (2000)
	*	Pierce et al., "Regulation of Vascular Endothelial Growth Factor by Oxygen in a Model of Retinopathy of Prematurity," Arch Ophthalmol 114:1219-1228 (1996)
	*	Player and Torrence, "The 2-5A System: Modulation of Viral and Cellular Processes Through Acceleration of RNA Degradation," *Pharmacol Ther.* 78:55-113 (1998)
	*	Plouët et al., "Isolation and characterization of a newly identified endothelial cell mitogen produced by AtT-20 cells," *The EMBO Journal* 8:3801-3806 (1989)
	*	Praseuth et al., "Triple helix formation and the antigene for sequence-specific control of gene expression," *Biochimica et Biophysica Acta* 1489:181-206 (1999)

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

McDONNELL BOEHNEN
HULBERT & BERGHOFF LLP
300 SOUTH WACKER DRIVE
CHICAGO, ILLINOIS 60606
TELEPHONE (312) 913-0001

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No.	Serial No.
		04-736 (400/134)	10/683,990
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Applicant:	
	(Use several sheets if necessary)	McSwiggen et al.	
		Filing Date:	Group:
		October 10, 2003	1635

	*	Puttaraju et al., "A circular trans-acting hepatitis delta virus ribozyme," Nucleic Acids Research 21:4253-4258 (1993)
	*	Pyle et al., "Building a Kinetic Framework for Group II Intron Ribozyme Activity: Quantitation of Interdomain Binding and Reaction Rate," Biochemistry 33:2716-2725 (1994)
	*	Quereda et al., "Individual and Combined Effects of Triptoreline and Gestrinone on Experimental Endometriosis in Rats," European Obstetrics & Gynecology and Reproductive Biology 67:35-40 (1996)
	*	Randall et al., "Clearance of replicating hepatitis C virus replicon RNAs in cell culture by small interfering RNAs," *PNAS,* 100, 235-240 (2003)
	*	Robertson et al., "Purification and Properties of a Specific *Escherichia coli* Riobnuclease which Cleaves a Tyrosine Transfer Ribonucleic Acid Precursor," J. Biol. Chem. 247:5243-5251 (1972)
	*	Robinson et al., "Oligodeozynucleotides Inhibit Retinal Neovascularization in a Murine Model of Proliferation Retinopathy," Proc. Natl. Acad. Sci. USA 93: 4851- 4856 (1996)
	*	Rossi et al., "Ribozymes as Anti-HIV-1 Therapeutic Agents: Principles, Applications, and Problems," Aids Research and Human Retroviruses 8:183-189 (1992)
	*	Ruoslahti, "RGD and Other Recognition Sequences for Integrins," Annu. Rev. Cell Dev. Biol. 12:697-715 (1996)
	*	Salo et al., "Aminooxy Functionalized Oligonucleotides: Preparation, On-Support Derivatization, and Postsynthetic Attachment to Polymer Support," Bioconjugate Chem. 10:815-823 (1999)
	*	Sanghvi et al., "Improved Process for the Preparation of Nucleosidic Phosphoramidites Using a Safer and Cheaper Activator," Organic Process Res. & Dev. 4:175-181 (2000)
	*	Santoro and Joyce, "A general purpose RNA-cleaving DNA enzyme," Proc. Natl. Acad. Sci. USA 94:4262-4266 (1997)

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

McDONNELL BOEHNEN
HULBERT & BERGHOFF LLP
300 SOUTH WACKER DRIVE
CHICAGO, ILLINOIS 60606
TELEPHONE (312) 913-0001

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No.	Serial No.
		04-736 (400/134)	10/683,990
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Applicant:	
	(Use several sheets if necessary)	McSwiggen et al.	
		Filing Date:	Group:
		October 10, 2003	1635

	*	Santoro et al., "Mechanism and Utility of an RNA-Cleaving DNA Enzyme," *Biochemistry* 37:13330-13342 (1998)
	*	Santoro et al., "RNA Cleavage by a DNA Enzyme with Extended Chemical Functionality," *J. Am. Chem. Soc.* 122:2433-2439 (2000)
	*	Saville and Collins, "A Site-Specific Self-Cleavage Reaction Performed by a Novel RNA In Neurospora Mitochondria," Cell 61:685-696 (1990)
	*	Saville and Collins, "RNA-Mediated Ligation of Self-Cleavage Products of a *Neurospora* Mitochondrial Plasmid Transcript," Proc. Natl. Acad. Sci. USA 88:8826-8830 (1991)
	*	Schmajuk et al., "Antisense Oligonucleotides with Different Backbones," *The Journal of Biological Chemistry* 274:21783-21789 (1999)
	*	Schmidt et al., "Base and sugar requirements for RNA cleavage of essential nucleoside residues in internal loop B of the hairpin ribozyme: implications for secondary structure," Nucleic Acids Research 24:573-581 (1996)
	*	Schwarze et al., "In Vivo Protein Transduction: Delivery of a Biologically Active Protein into the Mouse," Science 285:1569-1572 (1999)
	*	Scott et al., "The crystal structure of an All-RNA hammerhead ribozyme: A proposed mechanism for RNA catalytic cleavage," Cell 81:991-1002 (1995)
	*	Shalaby *et al.*, "Failure of Blood-island Formation and Vasculogenesis in Flk-1-deficient Mice," 1995 *Nature* 376, 62
	*	Sharkey et al., "Vascular Endothelial Growth Factor Expression in Human Endometrium is Regulated by Hypoxia," The Journal of Clinical Endocrinology & Metabolism 85:402-409 (2000)
	*	Shibuya et al., "Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (*flt*) closely related to the *fms* family," Oncogene 5:519-524 (1990)
	*	Silverman et al., "Selective RNA Cleavage by Isolated RNase L Activated with 2-5A Antisense Chimeric Oligonucleotides," *Methods in Enzymology* 313:522-533 (1999)

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

McDONNELL BOEHNEN
HULBERT & BERGHOFF LLP
300 SOUTH WACKER DRIVE
CHICAGO, ILLINOIS 60606
TELEPHONE (312) 913-0001

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No.	Serial No.
		04-736 (400/134)	10/683,990
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant: McSwiggen et al.	
		Filing Date: October 10, 2003	Group: 1635

	40.	Snyder et al., "Defining Genes in the Genomics Era," *Science,* 300, 258-260 (2003)
	*	Stein and Cheng, "Antisense Oligonucleotides as Therapeutic Agents - Is the Bullet Really Magical?" Science 261:1004-1288 (1993)
	*	Stein et al., "A Specificity Comparison of Four Antisense Types: Morpholino, 2'-O-Methyl RNA, DNA, and Phosphorothioate DNA," Antisense & Nucleic Acid Drug Development 7:151-157 (1997)
	*	Stoeckemann et al., "Effects of the Progesterone Antagonists Onapristone (ZK 98 299) and ZK 136 799 on Surgically Induced Endometriosis in Intact Rats," Human Reproduction 10:3264-3271 (1995)
	*	Strobel and Dervan, "Site-Specific Cleavage of a Yeast Chromosome by Oligonucleotide-Directed Triple-Helix Formation," *Science* 249:73-75 (1990)
	*	Strobel et al., "Exocyclic Amine of the Conserved G·U Pair at the Cleavage Site of the *Tetrahymena* Ribozyme Contributes to 5'-Splice Site Selection and Transition State Stabilization," Biochemistry 35:1201-1211 (1996)
	*	Strobel et al., "Minor Groove Recognition of the Conserved G·U Pair at the *Tetrahymena* Ribozyme Reaction Site," Science 267:675-679 (1995)
	*	Sullenger and Cech, "Ribozyme-mediated repair of defective mRNA by targeted trans-splicing," Nature 371:619-622 (1994)
	*	Sullenger et al., "Overexpression of TAR Sequences Renders Cells Resistant to Human Immunodeficiency Virus Replication," Cell 63:601-608 (1990)
	*	Szostak and Ellington, "Ch. 20 - In Vitro Selection of Functional RNA Sequences," in The RNA World, edited by Gesteland and Atkins, Cold Spring Harbor Laboratory Press, pp. 511-533 (1993)
	*	Szostak, "*In Vitro* Genes," TIBS 17:89-93 (1993)
	*	Takeshita *et al.,* "Therapeutic Angiogenesis: A Single Intraarterial Blous of Vascular Endothelial Growth Factor Augments Revascularization in a Rabbit Ischemic Hind Limb Model," 1995 *J. Clin. Invest.* 93, 662

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

McDONNELL BOEHNEN
HULBERT & BERGHOFF LLP
300 SOUTH WACKER DRIVE
CHICAGO, ILLINOIS 60606
TELEPHONE (312) 913-0001

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No.	Serial No.
		04-736 (400/134)	10/683,990
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant: McSwiggen et al.	
		Filing Date: October 10, 2003	Group: 1635

	*	Tang et al., "Examination of the catalytic fitness of the hammerhead ribozyme by in vitro selection," RNA 3:914-925 (1997)
	*	Terman et al., "Identification of a new endothelial cell growth factor receptor tyrosine kinase," pp 1677-1683 (1991)
	*	Torrence et al., "Targeting RNA for degradation with a (2'-5') oligoadenylate-antisense chimera," Proc. Natl. Acad. Sci. USA 90:1300-1304 (1993)
	*	Uhlenbeck, "A Small Catalytic Oligoribonucleotide," Nature 328:596-600 (1987)
	*	Uhlmann and Peyman, "Antisense Oligonucleotides: A New Therapeutic Principle," Chemical Reviews 90:544-584 (1990)
	*	Usman et al., "Hammerhead ribozyme engineering," Current Opinion in Structural Biology 1:527-533(1996)
	*	Vaish et al., "Isolation of Hammerhead Ribozymes with Altered Core Sequences by *in Vitro* Selection," Biochemistry 36:6495-6501 (1997)
	*	Vaisman et al., "Characterization of the Receptors for Vascular Endothelial Growth," *The Journal of Biological Chemistry* 265:19461-19466 (1990)
	*	Wang et al., "Delivery of Antisense Oligodeoxyribonucleotides Against the Human Epidermal Growth Factor Receptor into Cultured KB Cells with Liposomes Conjugated to Folate via Polyethylene Glycol," Proc. Natl. Acad. Sci. USA 92:3318-3322 (1995)
	*	Warashina, et al., "Extremely High and Specific Activity of DNA Enzymes in Cells with a Philadelphia Chromosome, Chemistry & Biology, 6(4):237-250 (1999)
	*	Werner and Uhlenbeck, "The effect of base mismatches in the substrate recognition helices of hammerhead ribozymes on binding and catalysis," Nucleic Acids Research 23:2092-2096 (1995)
	*	Woolf et al., "Specificity of Antisense Oligonucleotides *in vivo*," Proc. Natl. Acad. Sci. USA 89:7305-7309 (1992)
	*	Wu and Kaufman, J. Biol. Chem., 272, 1921-1926 (1997)

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

McDONNELL BOEHNEN
HULBERT & BERGHOFF LLP
300 SOUTH WACKER DRIVE
CHICAGO, ILLINOIS 60606
TELEPHONE (312) 913-0001

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No.	Serial No.
		04-736 (400/134)	10/683,990
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Applicant:	
	(Use several sheets if necessary)	McSwiggen et al.	
		Filing Date:	Group:
		October 10, 2003	1635

	*	Yang et al., "Hydrodynamic injection of viral DNA: A mouse model of acute hepatitis B virus infection," *PNAS,* 99, 21, 13825-13830 (2002)
	41.	Yonekura et al., "Placenta Growth Factor and Vascular Endothelial Growth Factor B and C Expression in Microvascular Endothelial Cells and Pericytes," *The Journal of Biological Chemistry,* 274(49):35172-35178 (1999)
	*	Yuan et al., "Targeted cleavage of mRNA by human RNase P," Proc. Natl. Acad. Sci. USA 89:8006-8010 (1992)
	*	Zabner et al., "Adenovirus-Mediated Gene Transfer Transiently Corrects the Chloride Transport Defect in Nasal Epithelia of Patients with Cystic Fibrosis," Cell 75:207-216 (1993)
	*	Zarrinkar and Williamson, "The P9.1-P9.2 peripheral extension helps guide folding of the *Tetrahymena* ribozyme," Nucleic Acids Research 24:854-858 (1996)
	*	Zaug et al., "The *Tetrahymena* Ribozyme Acts Like an RNA Restriction Endonuclease," Nature 324:429-433 (1986)
	*	Zimmerly et al., "A Group II Intron RNA is a Catalytic Component of a DNA Endonuclease Involved in Intron Mobility," Cell 83:529-538 (1995)
	*	Zinnen et al., "Chemically Modified siRNAa: Potential Anti-viral Hepatitis Therapeutics" (Abstract) March 2004
	42.	Autiero et al., "Role of P1GF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1," *Nature Medicine,* 9(7):936-942 (2003)

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

McDONNELL BOEHNEN
HULBERT & BERGHOFF LLP
300 SOUTH WACKER DRIVE
CHICAGO, ILLINOIS 60606
TELEPHONE (312) 913-0001